GE Healthcare Technologies presents a defensive valuation profile trading at 15.24x trailing earnings, representing a 29% discount to its 52-week high of $89.77. The company's beta of 0.82 signals below-market volatility, while systematic screening highlights an 18.75% return on equity alongside a net margin of 9.1%, indicating operational efficiency within the medical technology sector. Current pricing at $64.01 reflects recent pressure despite the firm's $29.1 billion market capitalization.

Fundamental analysis reveals several structural strengths:

• Margin resilience: The 39.14% gross margin and 12.63% operating margin demonstrate pricing power in imaging and diagnostic equipment markets, supporting cash generation despite cyclical healthcare capital expenditure patterns.
• Balance sheet positioning: A debt-to-equity ratio of 0.97 remains manageable for capital-intensive medical device manufacturing, while the 1.37 current ratio provides adequate short-term liquidity for working capital requirements.
• Revenue momentum: Year-over-year revenue growth of 5.97% outpaces broader healthcare equipment peers, reflecting sustained demand for diagnostic imaging and patient monitoring systems.

The model flags material risks, particularly the -12.27% year-over-year EPS decline suggesting margin compression or elevated operational costs. The 1.39x price-to-sales ratio appears elevated relative to the normalized earnings trajectory, while return on assets of 5.25% indicates capital intensity challenges inherent to the equipment manufacturing model.

Compared to peers including Stryker (SYK), Boston Scientific (BSX), and Edwards Lifesciences (EW), GEHC's 3.6x price-to-book ratio and broader diagnostic equipment exposure position the company differently from device-focused competitors, offering diversified healthcare infrastructure exposure with lower growth expectations.